GEN Exclusives

More »

GEN News Highlights

More »
Jul 12, 2007

Roche to Make $7.5M Milestone Payment to Pharmasset

  • Pharmasset and Roche have initiated long-term chronic toxicology studies in two animal species for the development of a HCV candidate as part of their collaboration. Roche will pay $7.5 million as a milestone fee. The compound, R7128, is currently in a Phase I trial. The primary objective of the toxicology research is to assess the safety of the drug when given for six months.

    "As we progress with the ongoing 14-day multiple ascending dose study of R7128, we are encouraged that Roche has initiated the long-term chronic toxicology studies in support of the potential advancement of R7128 into Phase II clinical trials," states Schaefer Price, Pharmasset's president and CEO.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?